Press Releases Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 20:00:00 10/03/2026 GMT			5-day change	1st Jan Change
59.20 ^USD	-2.42%		-7.64%	-10.83%

02-22	Certain Warrants of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI
02-22	Certain Options of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 22-FEB-2026.	CI

Press Releases

02-24	Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events	BU
02-05	Arrowhead Pharmaceuticals : ARWR FQ1 2026 Script Final	PU
02-05	Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results	BU
01-27	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia	BU
01-20	Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results	BU
01-08	Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants	BU
01-07	Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China	BU
01-06	Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock	BU
01-06	Arrowhead Pharmaceuticals : ARO INHBE and ARO ALK7 2025 Data Release Final	PU
01-06	Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition	BU
01-05	Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)	BU
12-23	Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events	BU
12-15	Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	BU
12-10	Arrowhead Pharmaceuticals : CNS Delivery Summit Dec 2025	PU
12-08	Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies	BU
12-08	Arrowhead Pharmaceuticals : Corporate Presentation Short Dec 2025	PU
12-04	Arrowhead Pharmaceuticals : WCIRDC 2025 SHASTA 3 and 4 Baseline	PU
12-04	Arrowhead Pharmaceuticals : WCIRDC 2025 Recurrent AP	PU
12-04	Arrowhead Pharmaceuticals : WCIRDC 2025 Monte Carlo Simulation	PU
12-04	Arrowhead Pharmaceuticals : WCIRDC 2025 Plozasiran QOL	PU
12-04	Arrowhead Pharmaceuticals : WCIRDC 2025 PALISADE OLE	PU
12-02	Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia	BU
12-01	Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences	BU
11-26	Arrowhead Pharmaceuticals : ARWR FQ4 2025 Script Final	PU
11-25	Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results	BU